ClinicalTrials.gg
RecruitingNCT03787602Updated Mar 2, 2023

Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

A Phase 1/2 interventional study of KRT-232 and Avelumab in Merkel Cell Carcinoma, sponsored by Kartos Therapeutics, Inc.. Recruiting at 51 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-02.

Sponsored by Kartos Therapeutics, Inc. (part of Ipsen) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Mar 2019; still recruiting 7 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Carcinoma, Merkel Cell with a site in United States — 26 open to participants now, 47 under way, 3 of them phase 3. Carcinoma, Merkel Cell · United States.

Planned enrollment
19th of 105
115 · median 40
Started
2019
with 14 others
Phase 1/2
27 of 112
9 open now
Primary completion
2024-11
later than 3 of 46 live
Registered
49th of 112
by date

Among the 112 studies in Carcinoma, Merkel Cell with a site in United States, this one is the 19th largest by planned enrollment of the 105 interventional ones that give a count, is one of 15 that started in 2019, is one of 27 in phase 1/2, reaches primary completion later than 3 of the 46 other live ones, and was the 49th registered.

Carcinoma, Merkel Cell

150 studies on the registry are indexed under Carcinoma, Merkel Cell; 39 are open to participants now.

Browse Carcinoma, Merkel Cell studies →

Open to participants now

26 of the 112 studies in Carcinoma, Merkel Cell with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Carcinoma, Merkel Cell studies recruiting now, 26 (79%) set no upper age limit and none (0%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Carcinoma, Merkel Cell with a site in United States, or all of them as a file.
02

Study summary

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.

03

Conditions studied

  • Merkel Cell Carcinoma

Keywords

  • navtemadlin (KRT-232)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Cohort 1, 3 and 4 patients must have failed treatment with at least one inhibitor or PD-L1 inhibitor for MCC
  • For Cohort 2, patients must not have received any anti-PD-1 or anti-PD-L1 therapy
  • For Cohort 3, patients must not have received any prior chemotherapy
  • For Cohort 4, patients must have received at least one
  • performance status of 0 to 1
  • confirmed MCC. Disease must be measurable, with at least 1 by 1.1
  • MCC expressing p53WT based on any CLIA or test approved by local health authority or a validated test (Cohort 1 and 2)
  • MCC expressing p53WT based Central Lab test (Cohort 3 and 4)
  • Adequate hematological, hepatic, and renal functions

Exclusion criteria

Exclusion Criteria:

  • For Cohort 2, subjects must not have disease, medical conditions requiring systemic , prior stem cell transplant, or active infection with or .
  • Patients previously treated with MDM2 antagonist therapies or p53-directed therapies
  • History of major organ transplant
  • Patients with known central nervous system (CNS) that are previously untreated
  • Grade 2 or higher prolongation (>480 milli-seconds per criteria, version 5.0)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
115 participants (estimated)

Study arms

  • Experimental
    Cohort 1, Arm 1

    KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 21-day cycle.

    Drug: KRT-232

  • Experimental
    Cohort 1, Arm 1b

    KRT-232 will be administered orally, once daily (QD) on Days 1-5 in a 23-day cycle.

    Drug: KRT-232

  • Experimental
    Cohort 1, Arm 2b

    KRT-232 will be administered orally, once daily (QD) on Days 1-5 in a 28-day cycle.

    Drug: KRT-232

  • Experimental
    Cohort 1, Arm 3

    KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 21-day cycle.

    Drug: KRT-232

  • Experimental
    Cohort 1, Arm 5

    KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle.

    Drug: KRT-232

  • Experimental
    Cohort 1 Expansion

    KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.

    Drug: KRT-232

  • Experimental
    Cohort 2, Arm 1 KRT-232 in combination with avelumab

    KRT-232 will be administered orally, once daily (QD) on Days 1-5, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.

    Drug: KRT-232 · Drug: Avelumab

  • Experimental
    Cohort 2, Arm 2 KRT-232 in combination with avelumab

    KRT-232 will be administered orally, once daily (QD) on Days 1-7, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.

    Drug: KRT-232 · Drug: Avelumab

  • Experimental
    Cohort 2 Expansion

    KRT-232 will be administered orally, once daily (QD) per RP2D dose and schedule, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.

    Drug: KRT-232 · Drug: Avelumab

  • Experimental
    Cohort 3

    KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.

    Drug: KRT-232

  • Experimental
    Cohort 4

    KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.

    Drug: KRT-232

Interventions

  • DrugNavtemadlinStudies of NavtemadlinNavtemadlin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    KRT-232 is an experimental MDM2 anticancer drug taken by mouth.

    Also known as: navtemadlin

  • Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.

    Also known as: Bavencio

06

What researchers measure

Primary outcomes

  1. Cohort 1 Part 1: To determine the KRT-232 RP2D.

    The Safety Review Committee (SRC) will determine RP2D for expansion based on safety and tolerability of each arm.

    Time frame: 10 Weeks

  2. Cohort 1 Part 2: To determine the objective response rate (ORR) in subjects with p53WT MCC who have failed anti-PD-1 or anti-PDL-1 immunotherapy

    ORR will be assessed per RECIST criteria version 1.1 after all subjects have been treated at the RP2D of KRT 232 and completed the second response assessment.

    Time frame: 10 Weeks

  3. Cohort 2 Part 1: To determine the KRT-232 RP2D in combination with avelumab

    DLTs will be used to establish the MTD of KRT-232 in combination with avelumab. SRC will determine the RP2D based on the safety of combination of KRT-232 with avelumab.

    Time frame: 28 Days

  4. Cohort 2 Part 2: To determine the objective response rate (ORR) in treatment-naïve subjects with p53WT MCC

    ORR will be assessed per RECIST criteria version 1.1 after all 30 subjects have been treated at the RP2D of in combination with avelumab and have completed the second response assessment.

    Time frame: 10 Weeks

  5. Cohort 3: To determine the confirmed overall response rate (ORR) based on IRC assessments in subjects with p53WT MCC are chemotherapy naive and have failed anti-PD-1/PD-L.

    ORR will be assessed per RECIST criteria 1.1 by IRC.

    Time frame: 10 Weeks

  6. Cohort 4: To determine the confirmed overall response rate (ORR) based on IRC assessments in subjects with p53WT MCC who have failed anti-PD-1 or anti-PDL-1 immunotherapy and have had least 1 line of prior chemotherapy.

    ORR will be assessed per RECIST criteria 1.1 by IRC.

    Time frame: 10 Weeks

Secondary outcomes

  1. To determine the confirmed ORR based on investigator assessment.

    ORR will be assessed per RECIST criteria 1.1 by investigators.

    Time frame: 1 year after last subject enrolled.

  2. To determine the duration of response (DoR)

    Time from documentation of response (CR or PR as determined by RECIST 1.1) until disease progression.

    Time frame: 1 year after last subject enrolled

  3. To determine Progression-free survival (PFS)

    Time from initial treatment until disease progression.

    Time frame: 1 year after last subject enrolled

  4. To determine overall survival (OS)

    Time from initial treatment until death from any cause.

    Time frame: 1 year after last subject enrolled

  5. To determine clinical benefit rate (CBR)

    PR, CR or stable disease that last at least 10 weeks, per IRC or investigator assessment.

    Time frame: 1 year after last subject enrolled.

07

Study locations

50 of 51 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2019 (actual). Primary completion is estimated for Nov 2024, 68 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2018
First posted
Dec 26, 2018
StartActual
Mar 19, 2019
Primary completionEst.
Nov 2024
CompletionEst.
Aug 2025
Last update
Mar 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03787602
Responsible party
Sponsor
First posted
Dec 26, 2018
Start date
Mar 19, 2019
Primary completion
Nov 2024 (estimated)
Completion
Aug 2025 (estimated)
Last update
Mar 2, 2023

Study contacts

John Mei
Contact
jmei@kartosthera.com
650-542-0136
Emily Houlihan
Contact
ehoulihan@kartosthera.com
401-954-8042

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Navtemadlin

Start the discussion